Background: In our previous study we found that half of the patients treated at the Nylon District Hospital tuberculosis (TB) treatment centre were seropositive. HIV does not only fuel the number of tuberculosis (TB) cases worldwide but it is also at least in part, responsible for the non-achievement of the 85% cure rate target. 
INTRODUCTION
Tuberculosis (TB) disease remains a public health problem worldwide especially in Africa and Asia. Before the advent of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), relatively low disease burden levels were attained by many countries as a result of better treatment outcome. HIV has not only been blamed for the alarming increase of TB cases worldwide but has also been accused of being responsible for the non achievement of the 85% cure rate target for identified TB cases set by World Health Organisation (WHO) and International Union for the fight Against Tuberculosis and Lung Diseases (IUATLD) (1) (2) (3) .
While some studies found comparable TB cure rates among HIV positive and HIV negative patients (4, 5) , others have reported lower cure rates among TB patients infected with HIV (6, 7) . On the other hand, higher case fatalities have unanimously been reported in TB/HIV co-infected patients (4) (5) (6) (7) (8) (9) . The risk of death in HIV positive patients presenting with TB disease October 2009 is approximately four times higher than that of HIV negative TB patients (10) . During the initial phase of TB treatment, the cause of death might be due to TB but after the intensive phase of treatment it is usually due to other HIV related complications (4) . The one year mortality rate of TB patients infected with HIV ranges from 20-35% (11) .
The impact of HIV on TB treatment outcome in Cameroon is worth to be analysed most especially as the incidence and prevalence of HIV remains high. In 2004, the national programme for the fight against TB reported that 40% of patients with smear positive pulmonary tuberculosis (SPPT) were HIV positive (12) .
The Nylon District Hospital (NDH) with its pioneer HIV/AIDS treatment programme (PREvention et Traitement Intégré du VIh-PRETIVI Project) set up by Médecin Sans Frontiéres/ Switzerland (MSF-CH) and a TB treatment and diagnosis centre provides an ideal setting for the evaluation of the impact of HIV on TB treatment outcome at district level. In this study we compare the TB treatment outcome of SPPT patients who did an HIV test and those who refused the test as well as compare the treatment outcome between the HIV positive and HIV negative SPPT patients from 2003 to 2005, all of whom were treated as outpatients (self-administered drugs) under routine programme conditions. Our findings will provide information on the adequacy of the present treatment strategy as per the National Tuberculosis Programme, at district hospitals or health centre levels where treatment is not daily supervised at least for the intensive phase of therapy, in a country with high HIV burden.
MATERIALS AND METHODS

Setting:
The Nylon District Hospital is a first line referral unit in the Nylon Health District. It also co-habits an HIV/AIDS (PRETIVI) project and a TB diagnosis and treatment centre since 2001. The PRETIVI project was the first of its kind in the Littoral, South West and West regions of Cameroon with over six million inhabitants providing comprehensive care to Persons Living With HIV/AIDS (PL W HIV/AIDS) at district level. The integration of both TB and HIV programmes gave the hospital a good reputation and attracted a lot of patients.
Case detection of tuberculosis is essentially passive. Patients who consulted at the hospital with a dry or productive cough for more than or equal to three weeks with or without chest pain, dyspnoea, haemoptysis, fever, night sweats, weight loss were requested to do a sputum test (three early morning sputum smear in three days). Patients with at least two of the three sputum smear positive for acid fast bacilli were declared SPPT and those who had never taken TB medications were considered as new cases.
Following the national guidelines (12) The results were given to the patients from the 48th hour after post-counselling by workers in the psychosocial department. HIV positive patients were automatically proposed to join the PRETIVI Project during post-counselling. A PRETIVI file was opened for patients with a positive response and he/she referred for medical consultation.
The definitions used for treatment outcome by the national guideline are similar to those recommended by WHO and the IUATLD. Treatment outcome was determined after six months for patients with new SPPT and after eight months for relapse cases. In this study the following operational definitions for the given treatment outcome variable were used:
Cured: Patient who presented a negative smear microscopic result at the end of the fifth month of treatment and finished the remaining month(s) of treatment.
Defaulted: Patient who after taking TB medications for one month abandoned for at least two months. Table 1 .
There was no association between HIV status and neither health district of residence nor treatment history. However there was a significant association between HIV status and gender (P = 0.001) as well as age group (P = 0.0003). Of the 166 females with SPPT tested for HIV, 75(45.2%) were HIV positive as opposed to 61(27.7%) males of the 220 tested, giving a female to male SPPT/HIV co-infection ratio of 1.6. The mean age at diagnosis of patients with SPPT infected with HIV (33.59 ± 9.3 years) is similar (P = 0.261,95% CI of the difference = -1.008 to 3.713) to that of SPPT patients negative for HIV (32.24 ± 12.2 years). Up to 95(69.9%) of all SPPT/HIV co-infected patients were aged between 25 to 44 years. Treatment outcome: Treatment results of the 420 patients diagnosed with SPPT showed an overall cure rate of 69%, a default rate of 23.6%, a 3.3% death rate, a 2.9% treatment completion rate, a 0.7% treatment failure rate and a transfer out rate of 0.5% ( Table 2 ).
As indicated in Table 3 , the cure rate for SPPT cases was 78.8% for HIV-negative patients and 58.8% for HIV positive patients. SPPT/HIV co-infected patients were less likely to be cured (OR 0.384, 95%CI 0.250-0.652) as compared to SPPT/HIV negative patients. The default rate for SPPT cases was 28.7% for HIVpositive patients and 16.8% for HIV-negative patients. SPPT/HIV co-infected patients were more likely to default (OR 1.991, 95%CI 1.150-3.285) than SPPT/HIVnegative patients. Likewise, the death rate of SPPT cases was 7.4% for HIV-positive patients and 0.4% for HIV -negative patients. SPPT/HIV co-infected patients were much more likely to die in the course of treatment [OR 19.759, .330] than SPPT/HIV -negative patients. All these differences remained significant even after adjusting for age, gender, treatment history and residence. Treatment completion, treatment failure and transferred out were not associated with HIV status. Likewise treatment outcome of SPPT was associated with HIV status both for new cases of TB (P = 0.0006) and for cases of relapse (P = 0.0056). The cure rate (59.8% versus 55.2%) and death rate (6.6% versus 10.3%) in co-infected new SPPT cases was more favorable compared to relapse co-infected SPPT cases. Meanwhile co-infected relapse patients had a better outcome when it came to default rate (27.6% versus 29%) and treatment failure (0% versus 0.9%).
The cure rate for SPPT patients tested for HIV was 71.8% as opposed to 38.2% for SPPT patients not tested for HIV. SPPT patients not tested for HIV were less likely to be cured [OR 0.244, 95%CI 0.099-0.445] compared to SPPT patients tested for HIV. The default rate for SPPT patients was 21% for those tested for HIV and 52.9% for those not tested for HIV. SPPT patients not tested for HIV were more likely to default [OR 4.236, 95%CI 2.281- 9 .991] than those tested. After adjusting for age, sex, residence and treatment history, the differences in cure rate and default rate remained significant (Table 4) . The other treatment outcomes were not significantly associated with HIV test acceptability.
DISCUSSION
The prevalence of HIV infection among SPPT patients in our study was 35.2%. We found that in patients with SPPT, HIV status was associated with gender and age. Women and adults aged 25 to 45 years were the most SPPT/HIV co-infected. The overall cure rate, default rate and death rate were 69%, 23.6% and 3.3% respectively. SPPT/HIV co-infected patients were significantly more likely to default from treatment, to die in the course of treatment or not to be cured compared to SPPT /HIV negative patients. Likewise SPPT patients not tested for HIV were significantly less cured and defaulted most compared to SPPT patients tested for HIV.
According to the third Demographic Health Survey (DHS III) of 2004 in Cameroon, the prevalence of HIV in the general population increases progressively from the age of 15 years and reaches a maximum of 10.3% in women aged 25 to 39 years and 8.6% in men aged 35 to 39 years (13) . These age groups are amongst the most co-infected in our study. Also, the modifying effect of HIV to the TB-gender association is also related to the higher prevalence of HIV infection in women (6.8%) as opposed to men (4.1%) in the general population as reported in the DHS III. Therefore, supporting the fact that HIV is a very potent risk factor for TB, either by increasing the risk of direct progression of primary disease to full blown disease or increasing the risk of reactivating latent bacilli (14) .
The female to male SPPT/HIV co-infection ratio of 1.6 in our study is similar to the female: male HIV ratio of 1.7 in the general population as in the DHS III (13) . Other common grounds between our TB/HIV co-infection study and the HIV study of the DHS III are the similar age group distribution in SPPT/HIV coinfection and HIV infection in the general population and the female dominance in HIV infection as well as SPPT/HIV infection. Thus, in a country where surveys are scarcely done, a reflection needs to be carried out on the use of SPPT/HIV co-infection rate as a proxy for the estimation of HIV prevalence in some areas of the country.
The overall cure rate of 69% in our study is slightly higher than the 61% obtained by Banerjee and colleagues in Ntcheu District hospital in Malawi (7) but lower than the 76% found by Van den Broek et al in Mwanza Tanzania (6) and 77% by EI Sony et al in Sudan (5) . This may be due to the fact that we used self-administered treatment as from day one except in severely ill patients who were treated as in-patients and discharged as soon as they got better. All the cited studies treated their patients with DOTS during the intensive phase and then ambulatory treatment during the continuation phase. The significantly higher cure rate of SPPT/HIV negative patients (but lower than the recommended 85%) compared to SPPT/HIV positive ones in our study was common to all the above settings and of almost similar proportions (5-7). Meanwhile Murray and colleagues (4) studying miners in South Africa found similar cure rates between TB/HIV positive (89%) and TB/HIV negative (88%) patients under very strict, regular follow-up and well organised programme conditions after excluding death cases.
Tuberculosis patients tested for HIV had a far better outcome compared to their non tested counterparts because they benefited from an integrated care package especially those with a positive result. The non tested ones either were very sick to be counselled, presented at a terminal phase or refused the test. As such they died in the course of treatment or defaulted because they did not offer the team the opportunity to manage them in their entirety. Similar findings were reported by Banerjee and colleagues in Malawi (7).
Our overall death rate of 3.3% is very small just as the default rate of 23.6% is very high compared with other studies (4, 6, 7) . This is probably due to an underestimation of the number of deaths. We did not put in place a system to identify the residence of patients or to actively search for those who abandoned their treatment. Most of the known dead cases die in the hospital for one reason or another. It is thus likely that a good proportion of the defaulted patients are likely dead cases. We also confirmed the high case fatalities in TB/HIV co-infected patients earlier reported by many authors (4-9).
Nylon residents had a better outcome because the HIV programme ran in the same hospital at the beginning would preferably enroll HIV positive patients living within the district and refer the others to the nearest treatment centres around their residents. Hence Nylon patients started benefiting from integrated care early enough while the others had to spend further time to adapt and be incorporated to other treatment sites. Distance would not explain the difference because locomotion is not a problem in a metropolitan city like Douala.
Strengths and limitations:
This paper is a follow-up to our previous publication on the prevalence of the HIV virus infection among tuberculosis patients in the Nylon District Hospital tuberculosis treatment centre (15) . It goes further to emphasize the rates of the various TB treatment outcomes in HIV positive versus HIV negative patients and HIV tested versus HIV non tested patients. It also brings forth the importance of an integrated patient care approach in TB and HIV programmes in order to attain the 85% cure rate target recommended by WHO.
Our data did not permit us to do survival analysis which would have permitted us to better appreciate the treatment outcome especially the mortality rates of the various groups. Also, the number of cases for some treatment outcome categories were small giving very wide or incalculable confidence intervals.
DOTS per say wasn't used in our setting because of the absence of the necessary logistics and human resources. Nonetheless an analysis to determine when patients abandoned treatment showed that there was no significant difference in the number of patients who defaulted before (intensive phase) or after (continuation phase) their first sputum control test (at the end of the second month of treatment).
In conclusion, SPPT/HIV co-infected patients significantly die more in the course of treatment, default more from treatment and are less likely to be cured from TB compared to SPPT/HIV negative patients. In the same way, SPPT patients not tested for HIV are significantly less cured and defaulted most compared to SPPT patients tested for HIV. In this light we therefore recommend that, not only should a system of active search for lost to follow-up patients be put to place, health personnel prescribing anti-TB drugs be provided with the necessary expertise to diagnose and manage HIV so that TB/HIV co-infected patients benefit from an integrated package of care in and out of the hospital. TB patients who refuse to do the HIV test or whose state of health does not permit them to be counselled should be considered HIV positive until proven otherwise.
